Exclusion Criteria:~* Severe or unstable medical condition that, in the opinion of the investigator or Sponsor,
would interfere with the patient's ability to complete the study assessments or would require the equivalent of
institutional or hospital care~* History or presence of clinically evident vascular disease potentially
affecting the brain~* History of severe, clinically significant (persistent neurologic deficit or structural
brain damage) central nervous system trauma~* Hospitalization within 4 weeks prior to screening~* Previous
treatment with MABT5102A or any other therapeutic that targets Abeta~* Treatment with any biologic therapy
within 5 half-lives or 3 months prior to screening, whichever is longer, with the exception of routinely
recommended vaccinations, which are allowed
